Abstract:Background While the past decades have seen an explosion of innovation in immunotherapies, most have failed in their clinical studies. One of the barriers encountered across these trials is that despite demonstrated cytoxicity, tumor immune evasion renders these treatments ineffective. Glioblastoma (GBM) is one of these tumors where experimental immunotherapeutics have continued to fail. The median survival of GBM remains at 15 months with the primary treatment being surgical resection, radiation, and chemotherapeutic over the past decade. To breach this stalemate, we require new therapeutics that both can target tumor immune evasion and can balance efficacy with toxicity. Our lab previously developed a subcutaneous autologous tumor vaccine utilizing a phagocytosis-stimulating ligand mannan anchored to irradiated (IR) tumor cells with the adjuvants toll-like receptor (TLR) agonists and immunostimulant anti-CD40 antibody (collectively abbreviated as MBTA). This regime allowed recognition of tumors resulting in a coordinated innate and adaptive immune response in both prophylactic and therapeutic studies with colon carcinoma, breast tumor, and GBM mouse models. The aim of our study was to generate a dendritic cell (DC) vaccine utilizing this strategy. Methods To assess if MBTA anchored GBM cells could mature DCs in-vitro, we harvested bone-marrow DCs (BMDCs) from mice and co-cultured them with MBTA GBM cells for 24 hours. Analysis was performed by flow cytometry and ELISA to confirm maturation markers and DC phenotype. To assess if MBTA DCs could protect against tumor metastasis, we utilized a melanoma (B16) prophylactic model by vaccinating mice 1 week before tail vein melanoma challenge. Results We found robust up-regulation of co-stimulatory molecules CD40, CD80 and CD86 and preferential upregulation of MHCI in the MBTA group with ELISA analysis demonstrating MBTA DCs significantly upregulated Type 1 cytokines (TNFa and IL-6) and limited regulatory cytokine (IL-10) secretion across GBM cell lines. Mice vaccinated with MBTA DCs had a significant decrease in lung metastasis compared to controls with lung immunohistochemistry demonstrating robust perivascular lymphocytic infiltration. Currently, we are working on demonstrating this efficacy in a glioblastoma model. Conclusions Collectively our results demonstrate that MBTA is an effective strategy to mature and load tumor antigens onto DCs ex-vivo. It has efficacy as a DC vaccine to prevent melanoma metastasis and potential as a glioblastoma DC vaccine. Acknowledgements The authors acknowledge the NCI-CCR affiliated staff for their assistance with animal housing and the NCI CCR Flow Cytometry Core Members for their expertise in flow cytometry Ethics Approval The National Cancer Institute (NCI) Animal Use and Care Committees approved the present study under NOB-010 and NOB-016.

Generation of CTL Responses Against Pancreatic Cancer in Vitro Using Dendritic Cells Co-Transfected with MUC4 and Survivin RNA.

Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro.

Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell.

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine

A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice.

Dendritic Cells Engineered to Secrete Anti-Dcr3 Antibody Augment Cytotoxic T Lymphocyte Response Against Pancreatic Cancer in Vitro

Therapeutic Vaccination Against Advanced Pancreatic Cancer by Autologous Dendritic Cells Pulsed with a MUC1 Peptide: Preclinical Results of a Clinical Phase I Trial

312P Identification of Neoantigen-Specific T Cell Response and Anti-Tumour Immunity in Pancreatic Cancer

Anti-colonic Cancer Effect in Vitro of MUC1 Specific CTLs Induced by MUC1 Core Peptide Tandem Repeats Gene-Modified Dendritic Cells Via Lentiviral Transduction

Dendritic Cells in Pancreatic Cancer Immunotherapy: Vaccines and Combination Immunotherapies.

A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer

The immunogenicity of the new MUC1 DNA vaccine for pancreatic cancer

Induction of antigen-specific CTL and antibody responses in mice by a novel recombinant tandem repeat DNA vaccine targeting at mucin 1 of pancreatic cancer

Immunotherapy of Intracranial G422 Glioblastoma with Dendritic Cells Pulsed with Tumor Extract or RNA

Increasing the Immune Activity of Exosomes: the Effect of Mirna-Depleted Exosome Proteins on Activating Dendritic Cell/cytokine-Induced Killer Cells Against Pancreatic Cancer.

425 A Novel Dendritic Cell Vaccine Utilizing Mannan Anchored to Irradiated Tumor Cells in the Presence of Immune Adjuvants

The optimized construction and cell transfection assay of new MUC1 DNA vaccine for pancreatic cancer

Prophylactic Dendritic Cell Vaccination Controls Pancreatic Cancer Growth in a Mouse Model.

Enhanced Therapeutic Efficacy Of Tumor Rna-Pulsed Dendritic Cells After Genetic Modification With Lymphotactin

Dendritic Cell Immunotherapy Induces Anti-Tumor Effect in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma.